Proteflazid®: outcome analysis of clinical trials studying the impact of human herpesvirus infection on some cellular immunity indicators and gestation course in women.

: An outcome analysis of the clinical trials evaluating the clinical and immunological efficacy of the drug Proteflazid® in the treatment of diseases associated with herpesvirus infection in pregnant women is presented. AIM: Objective of the study was to evaluate the effects of Proteflazid® on the cellular component of the immune system and gestation course in women with HHV infection by using meta-analysis and statistical analysis (based on Student's t-test) of the clinical findings. MATERIALS AND METHODS: The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 234 pregnant women during the period from 2003 to 2012. RESULTS: The obtained data prove the efficacy of the preparation Proteflazid ® in treating pregnant women with HHV infection. Administration of the drug Proteflazid® in the treatment of herpesvirus infection in pregnant women contributes to the cellular immunity normalization, which in turn has a positive effect on the course and outcome of pregnancy. CONCLUSIONS: Therapy with the drug Proteflazid® is etiologically and pathogenetically substantiated, contributes to the normalization of cellular immunity parameters, which, in turn, has a positive effect on the course and outcome of pregnancy.